Evidence map›Paper›PMID 39819489›Full record

ArticleeLife2025

A new preprocedural predictive risk model for post-endoscopic retrograde cholangiopancreatography pancreatitis: The SuPER model.

Mitsuru Sugimoto, Tadayuki Takagi, Tomohiro Suzuki, Hiroshi Shimizu, Goro Shibukawa, Yuki Nakajima, Yutaro Takeda, Yuki Noguchi, Reiko Kobayashi, Hidemichi Imamura and 7 more

Abstract readMulticenter StudyValidation Study
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Predictive models for post-ERCP pancreatitis: a systematic review and meta-analysis.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mitsuru SugimotoDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.ORCID https://orcid.org/0000-0002-4223-613X
Tadayuki TakagiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Tomohiro SuzukiDepartment of Gastroenterology, Fukushima Rosai Hospital, Iwaki, Japan.
Hiroshi ShimizuDepartment of Gastroenterology, Fukushima Rosai Hospital, Iwaki, Japan.
Goro ShibukawaDepartment of Gastroenterology, Aizu Medical Center, Fukushima Medical University, Aizu, Japan.
Yuki NakajimaDepartment of Gastroenterology, Aizu Medical Center, Fukushima Medical University, Aizu, Japan.
Yutaro TakedaDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Koriyama, Japan.
Yuki NoguchiDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Koriyama, Japan.
Reiko KobayashiDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Koriyama, Japan.
Hidemichi ImamuraDepartment of Gastroenterology, Ohta Nishinouchi Hospital, Koriyama, Japan.
Hiroyuki AsamaDepartment of Gastroenterology, Fukushima Redcross Hospital, Fukushima, Japan.
Naoki KonnoDepartment of Gastroenterology, Fukushima Redcross Hospital, Fukushima, Japan.
Yuichi WaragaiDepartment of Gastroenterology, Soma General Hospital, Soma, Japan.
Hidenobu AkatsukaDepartment of Gastroenterology, Saiseikai Fukushima General Hospital, Fukushima, Japan.
Rei SuzukiDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.
Takuto HikichiDepartment of Endoscopy, Fukushima Medical University Hospital, Fukushima, Japan.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University, School of Medicine, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal method for predicting PEP risk before ERCP has yet to be identified. We aimed to establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP. Methods: This multicenter study enrolled 2074 patients who underwent ERCP. Among them, 1037 patients each were randomly assigned to the development and validation cohorts. In the development cohort, the risk score model for predicting PEP was established via logistic regression analysis. In the validation cohort, the performance of the model was assessed. Results: In the development cohort, five PEP risk factors that could be identified before ERCP were extracted and assigned weights according to their respective regression coefficients: -2 points for pancreatic calcification, 1 point for female sex, and 2 points for intraductal papillary mucinous neoplasm, a native papilla of Vater, or the pancreatic duct procedures (treated as 'planned pancreatic duct procedures' for calculating the score before ERCP). The PEP occurrence rate was 0% among low-risk patients (≤0 points), 5.5% among moderate-risk patients (1-3 points), and 20.2% among high-risk patients (4-7 points). In the validation cohort, the C statistic of the risk score model was 0.71 (95% CI 0.64-0.78), which was considered acceptable. The PEP risk classification (low, moderate, and high) was a significant predictive factor for PEP that was independent of intraprocedural PEP risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation) (OR 4.2, 95% CI 2.8-6.3; p<0.01). Conclusions: The PEP risk score allows an estimation of the risk of PEP prior to ERCP, regardless of whether the patient has undergone pancreatic duct procedures. This simple risk model, consisting of only five items, may aid in predicting and explaining the risk of PEP before ERCP and in preventing PEP by allowing selection of the appropriate expert endoscopist and useful PEP prophylaxes. Funding: No external funding was received for this work.

Indexed as

Cholangiopancreatography, Endoscopic RetrogradePancreatitisAdultAgedFemaleHumansMaleMiddle AgedRandom AllocationRetrospective StudiesRisk AssessmentRisk FactorsERCPhumanmedicinepost-ERCP pancreatitispredictive risk model

Identifiers

PMID39819489
PMCPMC11741517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.